Brief: OSE Immunotherapeutics Announces Voluntary Pause Of Enrollment In CoVepiT Phase 1 Study

Ose Immunotherapeutics SA

19/07/2021 17:23

July 19 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * ANNOUNCES VOLUNTARY PAUSE OF ENROLLMENT IN THE COVEPIT
PHASE 1
STUDY
    * PAUSE WAS DECIDED AFTER RECEIVING A PRELIMINARY UPDATE BY
TRIAL'S PRINCIPAL INVESTIGATOR AT CENTER FOR VACCINOLOGY, GHENT
UNIVERSITY, REGARDING A LIMITED NUMBER OF GRADE 1 AND ONE GRADE
2 ADVERSE EVENTS
    * IN PARTICULAR, PERSISTENT NODULES AROUND INJECTION POINTS
(SUBCUTANEOUS, WITH NO PAIN, NO INFLAMMATION, NO FEVER, NO
IMPACT ON EVERYDAY LIFE AND WITHOUT ANY SYSTEMIC SYMPTOMS)
    * HAS DECIDED TO VOLUNTARILY PAUSE DOSING IN ITS ONGOING
CLINICAL
STUDY AND ASSESS EVOLUTION OF THESE NODULES BEFORE DETERMINING
BEST WAY FORWARD FOR THIS PRODUCT AND ITS TARGET POPULATION
    * WILL CAREFULLY REVIEW ALL AVAILABLE DATA TO DETERMINE
FUTURE
CLINICAL DEVELOPMENT STRATEGY OF COVEPIT

Source text for Eikon:  ID:nBw929Ppza 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))